Literature DB >> 29488240

Optical and pharmacological strategies of myopia control.

Pauline Kang1.   

Abstract

Recent increases in global myopia prevalence rates have raised significant concerns as myopia increases the lifelong risk of various sight-threatening ocular conditions. This growing public health burden has generated significant research interests into understanding both its aetiology and developing effective methods to slow down or stop its development, methods collectively termed 'myopia control'. The growing body of research has demonstrated benefits of various optical and pharmacological treatments resulting in myopia control management increasingly becoming a part of main stream clinical practice. This review will discuss the peer-reviewed literature on the efficacy of various myopia control interventions including multifocal spectacles and contact lenses, orthokeratology and pharmaceutical eye drops, as well as potential future research directions.
© 2018 Optometry Australia.

Entities:  

Keywords:  contact lenses; multifocal spectacles; myopia control; optical; orthokeratology; pharmacology

Mesh:

Substances:

Year:  2018        PMID: 29488240     DOI: 10.1111/cxo.12666

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN: 0816-4622            Impact factor:   2.742


  13 in total

1.  Bifocal & Atropine in Myopia Study: Baseline Data and Methods.

Authors:  Juan Huang; Donald O Mutti; Lisa A Jones-Jordan; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2019-05       Impact factor: 1.973

2.  Accommodation response and spherical aberration during orthokeratology.

Authors:  L Batres; S Peruzzo; M Serramito; G Carracedo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-12       Impact factor: 3.117

3.  Myopia Control With Multifocal Lens in School-Aged Children: A Meta-Analysis.

Authors:  Meilan Chen; Lu Xu; Hongyang Li; Fengping Cai; Hao Wang; Chun Hu; Yi Wu
Journal:  Front Pediatr       Date:  2022-06-20       Impact factor: 3.569

Review 4.  Myopia: Mechanisms and Strategies to Slow Down Its Progression.

Authors:  Andrea Russo; Alessandro Boldini; Davide Romano; Giuseppina Mazza; Stefano Bignotti; Francesco Morescalchi; Francesco Semeraro
Journal:  J Ophthalmol       Date:  2022-06-14       Impact factor: 1.974

5.  Weighted Zernike defocus coefficient of treatment zone is a meaningful indicator for myopia control efficacy of Ortho-K lenses.

Authors:  Yuzhuo Fan; Yan Li; Kai Wang; Jia Qu; Mingwei Zhao
Journal:  Eye Vis (Lond)       Date:  2022-07-01

6.  Effect of Combining 0.01% Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children.

Authors:  Jenny Huang Jones; Donald O Mutti; Lisa A Jones-Jordan; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2022-02-25       Impact factor: 2.106

Review 7.  The Combined Effect of Low-dose Atropine with Orthokeratology in Pediatric Myopia Control: Review of the Current Treatment Status for Myopia.

Authors:  José-María Sánchez-González; Concepción De-Hita-Cantalejo; María-José Baustita-Llamas; María Carmen Sánchez-González; Raúl Capote-Puente
Journal:  J Clin Med       Date:  2020-07-24       Impact factor: 4.241

8.  The effect of the optical design of multifocal contact lenses on choroidal thickness.

Authors:  Katharina Breher; Miguel García García; Arne Ohlendorf; Siegfried Wahl
Journal:  PLoS One       Date:  2018-11-16       Impact factor: 3.240

Review 9.  Efficacy and safety of interventions to control myopia progression in children: an overview of systematic reviews and meta-analyses.

Authors:  Efthymia Prousali; Anna-Bettina Haidich; Andreas Fontalis; Nikolaos Ziakas; Periklis Brazitikos; Asimina Mataftsi
Journal:  BMC Ophthalmol       Date:  2019-05-09       Impact factor: 2.209

10.  The Spatial Distribution of Relative Corneal Refractive Power Shift and Axial Growth in Myopic Children: Orthokeratology Versus Multifocal Contact Lens.

Authors:  Fan Jiang; Xiaopeng Huang; Houxue Xia; Bingqi Wang; Fan Lu; Bin Zhang; Jun Jiang
Journal:  Front Neurosci       Date:  2021-06-09       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.